Ames, Iowa, Feb. 17, 2015 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (Nasdaq:NLNK) today announced that management will participate in the SunTrust Robinson Humphrey One-on-One Orphan Drug Day on February 23, 2015 in New York. The event will bring together a select group of private and public biotechnology and biopharmaceutical companies focused on the development of highly innovative therapies for Orphan Diseases.
About NewLink Genetics Corporation
NewLink is a biopharmaceutical company focused on discovering, developing and commercializing novel immuno-oncology products to improve treatment options for patients with cancer. NewLink's portfolio includes biologic and small molecule immunotherapy product candidates intended to treat a wide range of oncology indications. NewLink's product candidates are designed to harness multiple components of the immune system to combat cancer without significant incremental toxicity, either as a monotherapy or in combination with other treatment regimens. For more information please visit http://www.linkp.com.
CONTACT: Investor Contact: Jack Henneman Chief Financial Officer (515) 598-2561 Investor@linkp.com
Source:NewLink Genetics Corporation